Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma

Acta Oncologica - United Kingdom
doi 10.3109/0284186x.2010.499370
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Activation of Insulin-Like Growth Factor 1 Receptor in Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2015English

The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2016English

Mutational Analysis of the Insulin-Like Growth Factor 1 Receptor Tyrosine Kinase Domain in Non-Small Cell Lung Cancer Patients

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Preclinical and First-In-Human Phase I Studies of KW-2450, an Oral Tyrosine Kinase Inhibitor With Insulin-Like Growth Factor Receptor-1/Insulin Receptor Selectivity

Cancer Science
Cancer ResearchMedicineOncology
2016English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

World Journal of Oncology
Cancer ResearchOncology
2019English

Phase I Clinical Trial of Human Vascular Endothelial Growth Factor Receptor 1 Peptide Vaccines for Patients With Metastatic Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2013English

190TiP: ELUXA 1: Phase II Study of BI 1482694 (HM61713) in Patients (Pts) With T790m-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy